SomaLogic (NASDAQ:SLGC) and Exact Sciences (NASDAQ:EXAS) are both business services companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.
Institutional and Insider Ownership
60.7% of SomaLogic shares are owned by institutional investors. Comparatively, 90.2% of Exact Sciences shares are owned by institutional investors. 1.4% of Exact Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This is a breakdown of current ratings and recommmendations for SomaLogic and Exact Sciences, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
SomaLogic presently has a consensus target price of $17.00, indicating a potential upside of 82.60%. Exact Sciences has a consensus target price of $138.75, indicating a potential upside of 76.91%. Given SomaLogic’s stronger consensus rating and higher probable upside, equities analysts clearly believe SomaLogic is more favorable than Exact Sciences.
Earnings & Valuation
This table compares SomaLogic and Exact Sciences’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Exact Sciences||$1.49 billion||9.06||-$848.53 million||($4.97)||-15.78|
SomaLogic has higher earnings, but lower revenue than Exact Sciences.
This table compares SomaLogic and Exact Sciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
SomaLogic beats Exact Sciences on 5 of the 9 factors compared between the two stocks.
SomaLogic Inc. provides AI-data driven proteomics technology. SomaLogic Inc., formerly known as CM Life Sciences II Inc., is based in NEW YORK.
About Exact Sciences
EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the early detection of colorectal cancer and pre-cancer. The company was founded on February 10, 1995 and is headquartered in Madison, WI.
Receive News & Ratings for SomaLogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SomaLogic and related companies with MarketBeat.com's FREE daily email newsletter.